FGFR2 and endometrial carcinoma: However, several ongoing clinical trials aim at exploiting targets supported by recent comprehensive molecular profiling of primary endometrial carcinoma lesion [1], dominated by trials targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) or FGFR2.